PT  - JOURNAL ARTICLE
AU  - Lewis, Sara A
AU  - Chopra, Maya
AU  - Cohen, Julie S.
AU  - Bain, Jennifer
AU  - Aravamuthan, Bhooma
AU  - Carmel, Jason B
AU  - Fahey, Michael C
AU  - Segel, Reeval
AU  - Wintle, Richard F
AU  - Zech, Michael
AU  - May, Halie
AU  - Haque, Nahla
AU  - Fehlings, Darcy
AU  - Srivastava, Siddharth
AU  - Kruer, Michael C
TI  - Clinical actionability of genetic findings in cerebral palsy
AID  - 10.1101/2023.09.08.23295195
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.08.23295195
4099  - http://medrxiv.org/content/early/2023/09/11/2023.09.08.23295195.short
4100  - http://medrxiv.org/content/early/2023/09/11/2023.09.08.23295195.full
AB  - Background and objectives Single gene mutations are increasingly recognized as causes of cerebral palsy (CP) phenotypes, yet there is currently no standardized framework for measuring their clinical impact. We evaluated Pathogenic/Likely Pathogenic (P/LP) variants identified in individuals with CP to determine how frequently genetic testing results would prompt changes in care.Methods We analyzed published P/LP variants in OMIM genes identified in clinical (n = 1,345 individuals) or research (n = 496) cohorts using exome sequencing of CP patients. We established a working group of clinical and research geneticists, developmental pediatricians, genetic counselors, and neurologists and performed a systematic review of existing literature for evidence of clinical management approaches linked to genetic disorders. Scoring rubrics were adapted, and a modified Delphi approach was used to build consensus and establish the anticipated impact on patient care. Overall clinical utility was calculated from metrics assessing outcome severity if left untreated, safety/practicality of the intervention, and anticipated intervention efficacy.Results We found 140/1,841 (8%) of individuals in published CP cohorts had a genetic diagnosis classified as actionable, defined as prompting a change in clinical management based on knowledge related to the genetic etiology. 58/243 genes with P/LP variants were classified as actionable; 16 had treatment options targeting the primary disease mechanism, 16 had specific prevention strategies, and 26 had specific symptom management recommendations. The level of evidence was also graded according to ClinGen criteria; 44.6% of interventions had evidence class “D” or below. The potential interventions have clinical utility with 97% of outcomes being moderate-high severity if left untreated and 62% of interventions predicted to be of moderate-high efficacy. Most interventions (71%) were considered moderate-high safety/practicality.Discussion Our findings indicate that actionable genetic findings occur in 8% of individuals referred for genetic testing with CP. Evaluation of potential efficacy, outcome severity, and intervention safety/practicality indicates moderate-high clinical utility of these genetic findings. Thus, genetic sequencing to identify these individuals for precision medicine interventions could improve outcomes and provide clinical benefit to individuals with CP. The relatively limited evidence base for most interventions underscores the need for additional research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by a CPARF project grant PRG06621 to SAL and supported by 1R01 1NS106298 and 1R01 1NS127108 to MCK. MCF was funded by the Australian-American Fulbright Commission. JSC is supported by NIH-NICHD (P50 HD103538). MZ receives research support from the German Research Foundation (DFG 458949627; ZE 1213/2-1). MZ acknowledges grant support by the EJP RD (EJP RD Joint Transnational Call 2022), the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the L&aumlnder, as well as by the Technical University of Munich Institute for Advanced Study. SS is supported by NIH-NINDS (K23NS119666). The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was reviewed by the Phoenix Children's Hospital IRB (IRB-23-260) and determined to be exempt from human subject research oversight and granted a waiver for patient consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData generated during this study including raw scores and Pubmed sampling script available on GitHub with access provided upon request. https://github.com/Kruer-Lab/actionability